Vγ9Vδ2 T lymphocytes activation in osteoporotic patients treated with bisphosphonates.
Vγ9Vδ2 T lymphocytes activation in osteoporotic patients treated with bisphosphonates. Clin Cases Miner Bone Metab. 2014 May;11(2):126-8 Authors: Sprini D, Di Stefano L, Rini GB, Cianferotti L, Napoli N Abstract Treatment with bisphosphonates induces differentiation and activation of Vγ9Vδ2 T lymphocytes obtained from peripheral blood showing also an antitumoral effect in both in vitro and in vivo models. Aim of the present study was to determine in vivo the effect of BPs treatment in patients affected with osteoporosis on Vγ9Vδ2 T lymphocytes. We have studied V&gamm...
Source: Clinical Cases in Mineral and Bone Metabolism - December 2, 2015 Category: Orthopaedics Tags: Clin Cases Miner Bone Metab Source Type: research

Zoledronic Acid–Induced Interface Dermatitis
In this report, we describe a 62-year-old woman who presented with diffuse, erythematous scaly plaques over the right thigh after 12 hours of infusion of ZA. Histopathologic examination of a skin biopsy from the right thigh revealed patchy scale crust containing neutrophils and inspissated serum, interface change with scattered individually necrotic keratinocytes, and a mild, superficial perivascular lymphocytic infiltrate with scattered eosinophils and pigment incontinence—findings consistent with an interface dermatitis. Given that the patient had no other systemic manifestations or laboratory abnormalities, to the...
Source: The American Journal of Dermatopathology - December 1, 2015 Category: Pathology Tags: Extraordinary Case Report Source Type: research

Surgical management of Bisphosphonate-related osteonecrosis of the jaw Stage II and III
Conclusions The results of the present study proof the effectiveness of surgical therapy for BRONJ stage II or III. (Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology)
Source: Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology - December 1, 2015 Category: ENT & OMF Source Type: research

BMP‐2 delivered via sucrose acetate isobutyrate (SAIB) improves bone repair in a rat open fracture model
Abstract Human bone morphogenetic proteins (BMPs) are an alternative to bone graft for the treatment of high‐energy open fractures. The standard delivery system for BMP‐2 is a porous collagen sponge, but we have previously found that the biocompatible, high viscosity carrier, Sucrose acetate isobutyrate (SAIB) is an effective and potentially less invasive alternative. The efficacy of SAIB as a BMP‐2 delivery system was examined in an open fracture model featuring a femoral osteotomy with periosteal stripping in 9w‐old male Sprague Dawley rats. SAIB containing BMP‐2 (SAIB/BMP‐2) was delivered into the fracture s...
Source: Journal of Orthopaedic Research - December 1, 2015 Category: Orthopaedics Authors: Tegan L Cheng, Aaron Schindeler, David G Little Tags: Research Article Source Type: research

Hypercalcaemia with disseminated osteolytic lesions: a rare presentation of childhood acute lymphoblastic leukaemia.
We report a 15-year-old boy with acute lymphoblastic leukaemia and hypercalcaemia. He had normal peripheral blood count and the peripheral smear did not show blast. The bone marrow examination revealed Pre B ALL phenotype with aberrant expression of CD13. The skeletal survey showed osteolytic lesions. Hypercalcaemia was treated with zoledronic acid. He attained remission only after three lines of intensive chemotherapy protocols. He was planned for stem cell transplant. Meanwhile, he relapsed and died. A review of the literature also highlights characteristics similar to our case. PMID: 26082799 [PubMed] (Source: Ecancermedicalscience)
Source: Ecancermedicalscience - November 29, 2015 Category: Cancer & Oncology Tags: Ecancermedicalscience Source Type: research

Potentiated suppression of Dickkopf-1 in breast cancer by combined administration of the mevalonate pathway inhibitors zoledronic acid and statins
Abstract The Wnt-inhibitor dickkopf-1 (DKK-1) promotes cancer-induced osteolytic bone lesions by direct inhibition of osteoblast differentiation and indirect activation of osteoclasts. DKK-1 is highly expressed in human breast cancer cells and can be suppressed by inhibitors of the mevalonate pathway such as statins and amino-bisphosphonates. However, supraphysiological concentrations are required to suppress DKK-1. We show that a sequential mevalonate pathway blockade using statins and amino-bisphosphonates suppresses DKK-1 more significantly than the individual agents alone. Thus, the reduction of the DKK-1 exp...
Source: Breast Cancer Research and Treatment - November 28, 2015 Category: Cancer & Oncology Source Type: research

Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review.
yha G Abstract Denosumab is an anti-RANK ligand (RANKL) monoclonal antibody approved for the treatment of postmenopausal osteoporosis and prevention of skeletal metastasis complications. Administered subcutaneously every 6months, it reduces the risk of vertebral fracture by 70% and of hip fracture by 40%. Its safety profile is acceptable. Denosumab may be used to treat patients with moderate to severe renal insufficiency. It has anti-fracture activity equivalent to that of zoledronic acid, but no residual effect, and no action at all beyond 6months. In France, denosumab is reimbursed as a second-line treatment aft...
Source: Annales d'Endocrinologie - November 27, 2015 Category: Endocrinology Authors: Diédhiou D, Cuny T, Sarr A, Norou Diop S, Klein M, Weryha G Tags: Ann Endocrinol (Paris) Source Type: research

Gastrointestinal events and association with initiation of treatment for osteoporosis
Conclusion: GI events after OP diagnosis were associated with a decreased likelihood of OP treatment initiation and an increased likelihood of treatment initiation with a non-bisphosphonate versus a bisphosphonate. Keywords: osteoporosis, postmenopausal, bisphosphonates, prescribing patterns (Source: ClinicoEconomics and Outcomes Research)
Source: ClinicoEconomics and Outcomes Research - November 25, 2015 Category: Health Management Tags: ClinicoEconomics and Outcomes Research Source Type: research

Titanium Dioxide-Grafted Copper Complexes: High-Performance Electrocatalysts for the Oxygen Reduction Reaction in Alkaline Media.
Abstract The sluggish kinetics of the oxygen reduction reaction (ORR) at the cathodes of fuel cells significantly hampers fuel cell performance. Therefore, the development of high-performance, non-precious-metal catalysts as alternatives to noble metal Pt-based ORR electrocatalysts is highly desirable for the large-scale commercialization of fuel cells. TiO2 -grafted copper complexes deposited on multiwalled carbon nanotubes (CNTs) form stable and efficient electrocatalysts for the ORR. The optimized catalyst composite CNTs@TiO2 -ZA-[Cu(phen${{^{{\rm NO}{_{2}}}}}$)(BTC)] shows surprisingly high selectivity for the...
Source: Chemistry - November 25, 2015 Category: Chemistry Authors: Wang FF, Wei PJ, Yu GQ, Liu JG Tags: Chemistry Source Type: research

The bisphosphonate zoledronic acid regulates key angiogenesis-related genes in primary human gingival fibroblasts
(Source: Archives of Oral Biology)
Source: Archives of Oral Biology - November 23, 2015 Category: Dentistry Authors: E.J. Ohlrich, D.E. Coates, M.P. Cullinan, T.J. Milne, S. Zafar, Y. Zhao, W.D. Duncan, G.J. Seymour Source Type: research

Zoledronic acid aggravates kidney damage during ischemia reperfusion injury in rat.
Authors: Sehitoglu I, Tumkaya L, Bedir R, Kalkan Y, Cure MC, Yucel AF, Zorba OU, Yuce S, Cure E Abstract INTRODUCTION: Zoledronic acid (ZA), a bisphosphonate, increases the levels of cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor alpha (TNF-α), and reactive oxygen species (ROS) in subjects without cancer. Increased production of ROS, TNF-α, and IL-6 during ischemia and reperfusion (I/R) injury stimulates apoptosis that leads to renal injury. We aimed to investigate whether ZA treatment has a protective effect on renal tissues during I/R. MATERIALS AND METHODS: Twenty-four Sprague-...
Source: Journal of Environmental Pathology, Toxicology and Oncology - November 20, 2015 Category: Environmental Health Tags: J Environ Pathol Toxicol Oncol Source Type: research

Oestrogen receptor positive breast cancer metastasis to bone: inhibition by targeting the bone microenvironment in vivo
Abstract Clinical trials have shown that adjuvant Zoledronic acid (ZOL) reduces the development of bone metastases irrespective of ER status. However, post-menopausal patients show anti-tumour benefit with ZOL whereas pre-menopausal patients do not. Here we have developed in vivo models of spontaneous ER+ve breast cancer metastasis to bone and investigated the effects of ZOL and oestrogen on tumour cell dissemination and growth. ER+ve (MCF7, T47D) or ER−ve (MDA-MB-231) cells were administered by inter-mammary or inter-cardiac injection into female nude mice ± estradiol. Mice were administere...
Source: Clinical and Experimental Metastasis - November 19, 2015 Category: Cancer & Oncology Source Type: research

New Non-Bisphosphonate Drugs that Produce Osteonecrosis of the Jaws
Conclusion: Denosumab, Sunitinib or Bevacizumab are causal agents in the development of ONJ. The combination of any of these along with BPs could increase the risk of developing ONJ over that posed by BP treatment alone. (Source: Oral health and Preventive dentistry)
Source: Oral health and Preventive dentistry - November 18, 2015 Category: Dentistry Source Type: research

Hypoxia-reperfusion affects osteogenic lineage and promotes sickle cell bone disease
Sickle cell disease (SCD) is a worldwide distributed hereditary red cell disorder, characterized by severe organ complication. Sickle bone disease (SBD) affects a large part of the SCD patient population, and its pathogenesis has been only partially investigated. Here, we studied bone homeostasis in a humanized mouse model for SCD. Under normoxia, SCD mice display bone loss and bone impairment, with increased osteoclast and reduced osteoblast activity. Hypoxia/reperfusion (H/R) stress, mimicking acute vaso-occlusive crises (VOCs), increased bone turnover, osteoclast activity (RankL), and osteoclast recruitment (Rank) with ...
Source: Blood - November 12, 2015 Category: Hematology Authors: Carbonare, L. D., Matte', A., Valenti, M. T., Siciliano, A., Mori, A., Schweiger, V., Zampieri, G., Perbellini, L., De Franceschi, L. Tags: Sickle Cell Disease, Red Cells, Iron, and Erythropoiesis Source Type: research

Effects of zoledronic acid on bone fusion in osteoporotic patients after lumbar fusion
The objective of the study was to explore the effects of zoledronic acid on the healing process in osteoporotic patients following spinal fusion in a randomized, placebo-controlled, and triple-blinded study. Methods Seventy-nine osteoporotic patients with single-level degenerative spondylolisthesis were randomly assigned to receive either zoledronic acid infusion (zoledronic acid group) or saline infusion (controls) after spinal fusion. Functional radiography and CT scans were used to evaluate fusion status. Bone formation was graded into three categories: Grade A (bridging bone bond...
Source: Osteoporosis International - November 10, 2015 Category: Orthopaedics Source Type: research

Role of intravenous dosage regimens of bisphosphonates in relation to other aetiological factors in the development of osteonecrosis of the jaws in patients with myeloma
In conclusion, treatment with zoledronic acid, high doses of pamidronic acid, and the coexistence of diabetes mellitus seem to be associated with the development of BRONJ. (Source: British Journal of Oral and Maxillofacial Surgery)
Source: British Journal of Oral and Maxillofacial Surgery - November 8, 2015 Category: ENT & OMF Source Type: research

Zoledronic Acid Use and Risk of Cognitive Decline among Elderly Women and Men with Osteoporosis.
Conclusions Among elderly woman and men with osteoporosis, cognitive functions remained stable 12 months after the administration of first-ever zoledronic acid. PMID: 26530338 [PubMed - as supplied by publisher] (Source: Endocrine, Metabolic and Immune Disorders Drug Targets)
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - November 6, 2015 Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research

Synthesis and biological evaluation of novel platinum complexes of imidazolyl-containing bisphosphonates as potential anticancer agents.
Abstract Four novel platinum complexes, [Pt(en)]2ZL (1), [Pt(en)]2IPrBP (2), [Pt(en)]2MIBP (3) and [Pt(en)]2EIBP (4) [en = ethylenediamine; ZL = 1-hydroxy-3-(1H-imidazol-1-yl)ethane-1,1-diylbisphosphonic acid, commonly known as zoledronic acid; IPrBP = 1-hydroxy-3-(1H-imidazol-1-yl)propane-1,1-diylbisphosphonic acid; MIBP = 1-hydroxy-2-(2-methyl-1H-imidazol-1-yl)ethane-1,1-diylbisphosphonic acid; EIBP = 1-hydroxy-2-(2-ethyl-1H-imidazol-1-yl)ethane-1,1-diylbisphosphonic acid], were prepared and evaluated against five human cancer cell lines, including U2OS, A549, HC...
Source: Journal of Biological Inorganic Chemistry : JBIC - November 3, 2015 Category: Chemistry Authors: Qiu L, Lv G, Cao Y, Chen L, Yang H, Luo S, Zou M, Lin J Tags: J Biol Inorg Chem Source Type: research

Oral delivery of zoledronic acid by non-covalent conjugation with lysine-deoxycholic acid: in vitro characterization and in vivo anti-osteoporotic efficacy in ovariectomized rats.
Abstract We assessed the possibility of changing the route of administration of zoledronic acid to an oral dosage form and its therapeutic efficacy in an estrogen-deficient osteoporosis rat model. To enhance oral bioavailability, we formed an ionic complex by electrostatic conjugation of zoledronic acid with lysine-linked deoxycholic acid (Lys-DOCA, an oral absorption enhancer). After forming the complex, the characteristic crystalline features of pure zoledronic acid disappeared completely in the powder X-ray diffractogram and differential scanning calorimetry thermogram, indicating that zoledronic acid existed i...
Source: European Journal of Pharmaceutical Sciences - November 2, 2015 Category: Drugs & Pharmacology Authors: Jeon OC, Seo DH, Kim HS, Byun Y, Park JW Tags: Eur J Pharm Sci Source Type: research

Dosing Strategies of Bone-Targeting Agents
In Reply We appreciate the comments by Hutton et al regarding dosing frequency and the need to examine alternative dosing intervals. Given our study design, which used a single infusion, we do not know whether a different dosing interval would have been more or less effective or generated more or fewer adverse events in this cohort. However, because a single infusion of zoledronic acid has been shown to exert a positive effect on skeletal health for up to 5 years, we chose a 2-year dosing interval. We agree that additional research needs to be done on the dosing frequency, especially focusing on frail elderly patients for ...
Source: JAMA Internal Medicine - November 1, 2015 Category: Internal Medicine Source Type: research

[In Process Citation].
lma J Abstract The tendency for bisphosphonate and non-bisphosphonate (eg.: antiresorptive or anti-angiogenesis drugs) induced osteonecrosis is increasing. Treatment of these patients is a challenge both for dentists and for oral and maxillofacial surgeons. Cooperation with the drug prescribing general medicine colleagues to prevent osteonecrosis is extremely important. Furthermore, prevention should include dental focus elimination, oral hygienic instructions and education, dental follow-up and, in case of manifest necrosis, referral to maxillofacial departments. Authors outline the difficulties of conservative a...
Source: Orvosi Hetilap - November 1, 2015 Category: Journals (General) Authors: Soós B, Vajta L, Szalma J Tags: Orv Hetil Source Type: research

Spontaneous Bilateral Femoral Fractures After High-Dose Zoledronic Acid.
Abstract The authors report a case of spontaneous bilateral diaphyseal femoral fractures believed to be caused by oversuppression of bone remodeling as a result of long-term, high-dose treatment with bisphosphonate. The patient reported pain in both thighs before the fractures. Typical pathologic changes appeared on both femoral radiograph and bone scan before the fractures. Several hours after admission to the emergency department of the authors' institution, the patient underwent closed reduction and internal fixation with intramedullary nails for the bilateral femoral diaphyseal fractures. Treatment with zoledr...
Source: Orthopedics - November 1, 2015 Category: Orthopaedics Authors: Brin YS, Palmanovich E, Heler Z, Kish BJ, Nyska M, Bismuth H, Coughlin R, Zehavi T, Rotman P Tags: Orthopedics Source Type: research

O3-14-3 * Impairment of renal function in the breast cancer patients with bone metastases treated with zoledronic acid
(Source: Annals of Oncology)
Source: Annals of Oncology - October 31, 2015 Category: Cancer & Oncology Authors: Ito, T., Ono, M., Oba, T., Hanamura, T., Kanai, T., Maeno, K., Hiraguri, M., Shingu, K., Kaneko, G., Ito, K.-i. Tags: Oral session Source Type: research

Antioxidant effects of bisphosphonates in smoking- induced lung injury in rat model
The study aimed to investigate the antioxidant effects of zoledronic acid on prevention of the lung injury caused by cigarette smoke induced oxidative stress in an animal model.The first rat group was exposed to cigarette smoke (CS), and the second group was given subcutaneous zoledronic acid with cigarette smoke exposure (ZCS). The accumulation rate of fibroblasts at the interstitial space was significantly higher in the CS group (21.5±7.83% in CS - 9.5±4.37% in ZCS, P=0.02). Table 1CS %ZCS %PMacrophages60.5±12.1262±15.67NAFibroblast21.5±7.839.5±4.370,02Lymphoplasmacytic cell15&p...
Source: European Respiratory Journal - October 30, 2015 Category: Respiratory Medicine Authors: Korkmaz, C., Yavsan, D. M., Demirbas, S., Oltulu, P., Kilinc, I., Uyar, M., Gok, M., Uzun, K. Tags: 5.1 Airway Pharmacology and Treatment Source Type: research

Bisphosphonate-adsorbed ceramic nanoparticles increase bone formation in an injectable carrier for bone tissue engineering
Sucrose acetate isobutyrate (SAIB) is a sugar-based carrier. We have previously applied SAIB as a minimally invasive system for the co-delivery of recombinant human bone morphogenetic protein-2 (rhBMP-2) and found synergy when co-delivering zoledronic acid (ZA) and hydroxyapatite (HA) nanoparticles. Alternative bioceramics were investigated in a murine SAIB/rhBMP-2 injection model. Neither beta-tricalcium phosphate (TCP) nor Bioglass (BG) 45S5 had a significant effect on bone volume (BV) alone or in combination with the ZA. 14C-labelled ZA binding assays showed particle size and ceramic composition affected binding with na...
Source: Journal of Tissue Engineering - October 27, 2015 Category: Biotechnology Authors: Cheng, T. L., Murphy, C. M., Ravarian, R., Dehghani, F., Little, D. G., Schindeler, A. Tags: Original Article Source Type: research

Dual-therapy with αvβ3-targeted Sn2 lipase-labile Fumagillin-prodrug Nanoparticles and Zoledronic Acid in the Vx2 Rabbit Tumor Model
Publication date: Available online 27 October 2015 Source:Nanomedicine: Nanotechnology, Biology and Medicine Author(s): Alison K. Esser, Anne H. Schmieder, Michael H. Ross, Jingyu Xiang, Xinming Su, Grace Cui, Huiying Zhang, Xiaoxia Yang, John S. Allen, Todd Williams, Samuel A. Wickline, Dipanjan Pan, Gregory M. Lanza, Katherine N. Weilbaecher Fumagillin, an unstable anti-angiogenesis mycotoxin, was synthesized into a stable lipase-labile prodrug and incorporated into integrin-targeted lipid-encapsulated nanoparticles (αvβ3-Fum-PD NP). Dual anti-angiogenic therapy combining αvβ3-Fum-PD...
Source: Nanomedicine: Nanotechnology, Biology and Medicine - October 27, 2015 Category: Nanotechnology Source Type: research

Dual-therapy with αβ-targeted Sn2 lipase-labile Fumagillin-prodrug Nanoparticles and Zoledronic Acid in the Vx2 Rabbit Tumor Model
Fumagillin, an unstable anti-angiogenesis mycotoxin, was synthesized into a stable lipase-labile prodrug and incorporated into integrin-targeted lipid-encapsulated nanoparticles (αvβ3-Fum-PD NP). Dual anti-angiogenic therapy combining αvβ3-Fum-PD NP with zoledronic acid (ZA), a long-acting osteoclast inhibitor with proposed anti-angiogenic effects, was evaluated. In vitro, αvβ3-Fum-PD NP reduced (p (Source: Nanomedicine : Nanotechnology, Biology, and Medicine)
Source: Nanomedicine : Nanotechnology, Biology, and Medicine - October 26, 2015 Category: Nanotechnology Authors: Alison K. Esser, Anne H. Schmieder, Michael H. Ross, Jingyu Xiang, Xinming Su, Grace Cui, Huiying Zhang, Xiaoxia Yang, John S. Allen, Todd Williams, Samuel A. Wickline, Dipanjan Pan, Gregory M. Lanza, Katherine N. Weilbaecher Source Type: research

N32 * Denosumab after bone progression with zoledronic acid: a single center experience
(Source: Annals of Oncology)
Source: Annals of Oncology - October 26, 2015 Category: Cancer & Oncology Authors: Pastorelli, D., Zovato, S., Solda, C. Tags: Session N. Simultaneous care Source Type: research

Zoledronate Therapy for the Pathological Humeral Fracture in Polyostotic Fibrous Dysplasia: A Case Report.
We presented the case of an FD patient with persistent elbow pain due to FD itself and nonunion of humeral fracture, which was ameliorated promptly by intravenous zoledronate therapies. This case illustrated the benefit of zoledronate treatment in patients with extensive polyostotic FD and pathological fractures of extremities. PMID: 26491505 [PubMed] (Source: Clin Med Res)
Source: Clin Med Res - October 24, 2015 Category: Research Authors: Ohno I, Higuchi C Tags: J Clin Med Res Source Type: research

The Clinical and Economic Burden of Skeletal Related Events in Austria, Czech Republic, Germany, Greece, Italy, Spain and Switzerland: a Comparison Between the use of Denosumab and Zoledronic Acid In Patients with Prostate Cancer And Bone Metastases
To estimate the total number of skeletal-related events (SREs), the associated hospital burden and direct medical costs when denosumab is used instead of zoledronic acid in patients with prostate cancer (PC) and bone metastases (BMs). (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: J Cristino, J Finek, N Maniadakis, M Perez Encinas, R Ikenberg, I Campos Tapias, P Jandova, DP Zahn, C Moser, L Bolognese, G Tritaki, F Gatta, G Hechmati Source Type: research

The Clinical and Economic Burden of Skeletal Related Events in Austria, Czech Republic, Germany, Greece, Italy, Spain and Switzerland: A Comparison Between the use of Denosumab and Zoledronic acid in Patients With Breast Cancer and Bone Metastases
To estimate the total number of skeletal-related events (SREs) prevented, related hospital burden and direct medical expenditure when denosumab is used instead of zoledronic acid for SRE prevention in seven European countries. (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: J Cristino, I Diel, J Finek, M Perez Encinas, N Maniadakis, R Ikenberg, I Campos Tapias, P Jandova, DP Zahn, C Moser, L Bolognese, G Tritaki, F Gatta, G Hechmati Source Type: research

A Time and Motion Study of Denosumab Subcutaneous Injection and Zoledronic Acid Intravenous Infusion in Patients with Metastatic Bone Disease in Belgium
In patients with bone metastases from solid tumours, denosumab (Dmab) subcutaneous (SC) injection represents an alternative formulation to zoledronic acid (Zol) intravenous (IV) infusion with a superior efficacy for skeletal-related events prevention. This observational Time and Motion study estimated treatment duration endpoints associated with Dmab SC injection and Zol IV use as monotherapy. (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: J Body, J Mebis, M Peeters, T Besse-Hammer, V Fikkert, E de Cock, S Tao, P Kritikou, F Gatta, G Hechmati Source Type: research

Results From a Time and Motion Study of Denosumab Subcutaneous Injection and Zoledronic Acid Intravenous Infusion in Patients with Metastatic Bone Disease From Italian Sites
Since 2011, denosumab (Dmab) subcutaneous (SC) injection is available as a superior treatment option in patients with bone metastases from solid tumours, compared with zoledronic acid (Zol) administered as an intravenous (IV) infusion. Although Zol was the mainstay treatment for skeletal-related events prevention, Dmab provides an alternative formulation to IV infusions. This Time and Motion study was conducted in Italy to estimate treatment duration endpoints associated with Dmab SC and Zol IV use. (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: P Pedrazzoli, A Caraceni, A Beano, V Adamo, F Testore, A Pigni, J Body, L Sgreccia, E de Cock, S Tao, P Kritikou, G Hechmati, F Gatta Source Type: research

Cost-Effectiveness of Zoledronic Acid Versus Alendronic Acid In The Treatment of Osteoporosis In Postmenopausal Egyptian Patients: Decision Analysis
To evaluate from the Ministry of Health perspective, over a five-year period, the cost-effectiveness of using zoledronic acid 5mg compared to that of alendronic acid in the treatment of osteoporosis in postmenopausal Egyptian patients. (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: H Elmansy, AB Metry, R Eldessouki, G Elsisi Source Type: research

Comparative Effectiveness and Cost-Effectiveness of Generic Alendronate, Risendronate, Denosumab and Zolendronic Acid for Secondary Prevention of Fragility Fractures - Perliminay Results
To evaluate the relative health gains and costs of secondary prevention of fractures with generic alendronate, risedronate, denosumab and zoledronic acid. (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: G Hagen Source Type: research

The bisphosphonate zoledronic acid effectively targets lung cancer cells by inhibition of protein prenylation.
In this study, we show that zoledronic acid, a third generation bisphosphonate, is effective in targeting lung cancer cells. This is achieved by the induction of apoptosis and inhibition of proliferation, through suppressing the activation of downstream Ras and EGFR signaling by zoledronic acid. The combination of zoledronic acid and paclitaxel or cisplatin (commonly used chemotherapeutic drugs for lung cancer) augmented the activity of either drug alone in in vitro lung cancer cellular system and in vivo lung xenograft mouse model. Importantly, zoledronic acid inhibits protein prenylation as shown by the increased levels ...
Source: Biochemical and Biophysical Research communications - October 20, 2015 Category: Biochemistry Authors: Xie F, Li P, Gong J, Zhang J, Ma J Tags: Biochem Biophys Res Commun Source Type: research

Diminished Progression of Periapical Lesions with Zoledronic Acid in Ovariectomized Rats
The aim of this study was to investigate the effects of systemically administered zoledronic acid (ZOL) on the progression of periapical lesions in estrogen-deficient rats. (Source: Journal of Endodontics)
Source: Journal of Endodontics - October 18, 2015 Category: Dentistry Authors: Marcelo Tadahiro Wayama, Hitoshi Yoshimura, Seigo Ohba, Hisato Yoshida, Shinpei Matsuda, Junichi Kobayashi, Motohiro Kobayashi, João Eduardo Gomes Filho, Kazuo Sano Tags: Basic Research Source Type: research

Synergistic Anti-Tumor Effects of Zoledronic Acid and Radiotherapy against Metastatic Hepatocellular Carcinoma.
Authors: Morii K, Aoyama Y, Nakamura S, Okushin H Abstract A 72-year-old man with advanced hepatocellular carcinoma and decompensated hepatitis C virus-related cirrhosis suffered from a metastatic femoral fracture. After undergoing radiotherapy, he was only treated with supportive care, except for the administration of zoledronic acid (ZA). Thereafter, the initially elevated serum α-fetoprotein and des-gamma carboxyprothrombin levels declined to within the normal ranges. Hepatic and metastatic adrenal tumors, distant from the radiation field, exhibited a surprising regression. ZA is known to inhibit the activ...
Source: Internal Medicine - October 17, 2015 Category: Internal Medicine Tags: Intern Med Source Type: research

Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway
In conclusion, synergistic apoptotic effect of the combination treatment is correlated with the block of the PI3K/Akt signal pathway in breast cancer cells. (Source: Tumor Biology)
Source: Tumor Biology - October 13, 2015 Category: Cancer & Oncology Source Type: research

Zoledronic acid-associated symmetrical drug-related intertriginous and flexural exanthema (SDRIFE): report of baboon syndrome in a woman with recurrent metastatic breast cancer after receiving zoledronic acid.
CONCLUSIONS:   Non-contact allergenic drug-induced baboon syndrome has most commonly been associated with antibiotics such as beta-lactams and penicillins.  Zoledronic acid-associated baboon syndrome has not previously been observed in cancer patients.  Baboon syndrome (SDRIFE variant) was observed in a woman with recurrent metastatic breast cancer after her first exposure to zoledronic acid.  In summary, SDRIFE can occur in oncology patients receiving zoledronic acid and zoledronic acid should be added to the list of medications associated with the potential to cause non-contact allergenic drug-induced...
Source: Dermatol Online J - October 9, 2015 Category: Dermatology Authors: Cohen PR Tags: Dermatol Online J Source Type: research

Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma
Conclusions Zoledronic acid may offer a mainstay of multidisciplinary treatment for patients with BM for the purpose of reducing SREs. Levels of serum BAP and urinary NTx do not appear reliable as indicators of amelioration of BM symptoms. (Source: Annals of Surgical Oncology)
Source: Annals of Surgical Oncology - October 7, 2015 Category: Cancer & Oncology Source Type: research

Combination therapy with zoledronic acid and cetuximab effectively suppresses growth of colorectal cancer cells regardless of KRAS status
This article is protected by copyright. All rights reserved. (Source: International Journal of Cancer)
Source: International Journal of Cancer - October 6, 2015 Category: Cancer & Oncology Authors: Junko Kato, Manabu Futamura, Masako Kanematsu, Siqin Gaowa, Ryutaro Mori, Toshiyuki Tanahashi, Nobuhisa Matsuhashi, Kazuhiro Yoshida Tags: Research Article Source Type: research

Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options
Conclusions The osteoclast-targeted agents zoledronic acid and denosumab decrease SREs in mCRPC, and the α-emitting radiopharmaceutical agent radium-223 improves survival and decreases symptomatic skeletal events. Limited data are available to guide the sequence and combination of BTAs with disease-modifying agents, although data support the use of osteoclast-targeted drugs with chemotherapy, androgen-targeted agents, and radium-223. Zoledronic acid does not reduce SREs when started prior to castration resistance, although osteoclast-targeted agents do improve outcomes when used in patients with asymptomatic to minim...
Source: European Urology - October 5, 2015 Category: Urology & Nephrology Source Type: research

Treatment of osteoporosis after alendronate or risedronate
Abstract Alendronate (ALN) and risedronate (RIS) are ideal as first-choice therapy options in the treatment of postmenopausal osteoporosis. What to do for patients who do not respond adequately to bisphosphonates has not been conclusively determined, but transitioning to other therapies should be considered. The aim of this article is to describe potential alternatives for patients switching from ALN or RIS to other therapies for osteoporosis. A systematic search of PubMed was conducted to find papers that evaluate the effects of switching therapies on fractures, bone mineral density (BMD), or bone turnover marker...
Source: Osteoporosis International - October 5, 2015 Category: Orthopaedics Source Type: research

Dosing of zoledronic acid with its anti-tumor effects in breast Cancer
Publication date: Available online 3 October 2015 Source:Journal of Bone Oncology Author(s): Xinmin Zhao, Xichun Hu Bisphosphonates have played an important role in the treatment of breast cancer, mainly in patients with bone metastasis, by reducing the risk of fracture, spinal cord compression, and hypercalcemia. Zoledronic acid, the most frequently used intravenous agent, has been traditionally administered on a monthly dosing schedule. Preclinical studies have demonstrated that zoledronic acid can inhibit angiogenesis, invasion, and adhesion of tumor cells. Several clinical studies of different timings and schedules...
Source: Journal of Bone Oncology - October 4, 2015 Category: Cancer & Oncology Source Type: research

Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models.
Authors: Toneri M, Miwa S, Zhang Y, Hu C, Yano S, Matsumoto Y, Bouvet M, Nakanishi H, Hoffman RM, Zhao M Abstract Bone metastasis is a frequent occurrence in prostate cancer patients and often is lethal. Zoledronic acid (ZOL) is often used for bone metastasis with limited efficacy. More effective models and treatment methods are required to improve the outcome of prostate cancer patients. In the present study, the effects of tumor-targeting Salmonella typhimurium A1-R were analyzed in vitro and in vivo on prostate cancer cells and experimental bone metastasis. Both ZOL and S. typhimurium A1-R inhibited the growth o...
Source: Oncotarget - October 3, 2015 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Zoledronic acid suppresses callus remodeling but enhances callus strength in an osteoporotic rat model of fracture healing
In this study, we demonstrated that the use of zoledronic acid does not impair fracture healing, but results in superior callus size and resistance at the fracture site, which could be the consequence of a lower rate of bone turnover due to its anti-catabolic effect. (Source: Bone)
Source: Bone - October 2, 2015 Category: Orthopaedics Authors: Y. Hao, X. Wang, L. Wang, Y. Lu, Z. Mao, S. Ge, K. Dai Tags: Original Full Length Article Source Type: research

Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis
In conclusion, this meta-analysis indicates that treatment with zoledronic acid was more effective than pamidronate disodium in the complete response assessments and the incidence of headache, an AE, was significantly lower in cancer patients with zoledronic acid. (Source: Medicine)
Source: Medicine - October 1, 2015 Category: Internal Medicine Tags: Research Article: Systematic Review and Meta-Analysis Source Type: research

European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications.
opean Myeloma Network Abstract The European Myeloma Network provides recommendations for the management of the most common complications of multiple myeloma. Whole body low-dose computed tomography is more sensitive than conventional radiography in depicting osteolytic disease and thus we recommend it as the novel standard for the detection of lytic lesions in myeloma (grade 1A). Myeloma patients with adequate renal function and bone disease at diagnosis should be treated with zoledronic acid or pamidronate (grade 1A). Symptomatic patients without lytic lesions on conventional radiography can be treated with zoled...
Source: Haematologica - October 1, 2015 Category: Hematology Authors: Terpos E, Kleber M, Engelhardt M, Zweegman S, Gay F, Kastritis E, van de Donk NW, Bruno B, Sezer O, Broijl A, Bringhen S, Beksac M, Larocca A, Hajek R, Musto P, Johnsen HE, Morabito F, Ludwig H, Cavo M, Einsele H, Sonneveld P, Dimopoulos MA, Palumbo A, Eu Tags: Haematologica Source Type: research